Skip to Content
Merck
CN

SML2624

Dexlansoprazole

≥98% (HPLC), Proton pump inhibitor, powder

Synonym(s):

(R)-(+)-Lansoprazole, (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H14F3N3O2S
CAS Number:
138530-94-6
Molecular Weight:
369.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD16294176

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dexlansoprazole, ≥98% (HPLC)

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

InChI key

MJIHNNLFOKEZEW-RUZDIDTESA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +142 to +158°, c = 1 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

Dexlansoprazole is a proton pump inhibitor. It is the active enantiomer of lansoprazole used to treat gastroesophageal reflux disease (GERD).
Proton pump inhibitor; Active enantiomer of lansoprazole to treat gastroesophageal reflux disease (GERD)

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000471375
0000471375
0000438272
0000438272
0000434835

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Khean Lee Goh et al.
Journal of neurogastroenterology and motility, 22(3), 355-366 (2016-03-05)
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as
Karen E Hansen et al.
Gastroenterology, 156(4), 926-934 (2018-11-18)
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service